Evidence map›Paper›PMID 33466686›Full record

ArticlePharmaceutics2021

Experimental and Computational Observations of Immunogenic Cobalt Porphyrin Lipid Bilayers: Nanodomain-Enhanced Antigen Association.

Jasmin Federizon, Conrard Giresse Tetsassi Feugmo, Wei-Chiao Huang, Xuedan He, Kazutoyo Miura, Aida Razi, Joaquin Ortega, Mikko Karttunen, Jonathan F Lovell

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Jasmin FederizonDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY 14260, USA.
Conrard Giresse Tetsassi FeugmoDepartment of Chemistry, the University of Western Ontario, London, ON N6A 3K7, Canada.
Wei-Chiao HuangDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY 14260, USA.
Xuedan HeDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY 14260, USA.
Kazutoyo MiuraLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.ORCID 0000-0003-4455-2432
Aida RaziDepartment of Anatomy and Cell Biology, McGill University, Montreal, QC H3A 0C7, Canada.
Joaquin OrtegaDepartment of Anatomy and Cell Biology, McGill University, Montreal, QC H3A 0C7, Canada.
Mikko KarttunenDepartment of Chemistry, the University of Western Ontario, London, ON N6A 3K7, Canada.ORCID 0000-0002-9052-884X
Jonathan F LovellDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY 14260, USA.ORCID 0000-0002-8626-3033
University at Buffalo, State University of New York · USMcGill University · CAWestern University · CANational Institutes of Health · US

Funding

Light-Triggered Drug Release in Primed Pancreatic TumorsR01EB017270 · NIBIB · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LOVELL, JONATHAN F · 2013 to 2021
$3.5M
Rationally-Designed, Spontaneous-Particleized Pfs48/45 for a Multivalent Malaria VaccineR01AI148557 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI JULIEN, JEAN-PHILIPPE, LOVELL, JONATHAN F · 2020 to 2024
$2.1M
NIAID NIH HHS R01 AI148557NIBIB NIH HHS R01 EB017270NIH HHS R01AI148557
6 · The paper itself

Abstract

Cobalt porphyrin phospholipid (CoPoP) can incorporate within bilayers to enable non-covalent surface-display of antigens on liposomes by mixing with proteins bearing a polyhistidine tag (his-tag); however, the mechanisms for how this occurs are poorly understood. These were investigated using the his-tagged model antigen Pfs25, a protein antigen candidate for malaria transmission-blocking vaccines. Pfs25 was found to associate with the small molecule aquocobalamin, a form of vitamin B12 and a cobalt-containing corrin macrocycle, but without particle formation, enabling comparative assessment. Relative to CoPoP liposomes, binding and serum stability studies indicated a weaker association of Pfs25 to aquocobalamin or cobalt nitrilotriacetic acid (Co-NTA) liposomes, which have cobalt displayed in the aqueous phase on lipid headgroups. Antigen internalization by macrophages was enhanced with Pfs25 bound to CoPoP liposomes. Immunization in mice with Pfs25 bound to CoPoP liposomes elicited antibodies that recognized ookinetes and showed transmission-reducing activity. To explore the physical mechanisms involved, we employed molecular dynamics (MD) simulations of bilayers containing phospholipid, cholesterol, as well as either CoPoP or NTA-functionalized lipids. The results show that the CoPoP-containing bilayer creates nanodomains that allow access for a limited but sufficient amount of water molecules that could be replaced by his-tags due to their favorable free energy properties allowing for stabilization. The position of the metal center within the NTA liposomes was much more exposed to the aqueous environment, which could explain its limited capacity for stabilizing Pfs25. This study illustrates the impact of CoPoP-induced antigen particleization in enhancing vaccine efficacy, and provides molecular insights into the CoPoP bilayer properties that enable this.

Indexed as

antigensbilayersmalariamolecular dynamicsparticlessimulationsvaccines

Identifiers

PMID33466686
PMCPMC7828809
OpenAlexW3119493459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.